These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 25327099)

  • 21. Association of pancreatitis with glucagon-like peptide-1 agonist use.
    Anderson SL; Trujillo JM
    Ann Pharmacother; 2010 May; 44(5):904-9. PubMed ID: 20371755
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin.
    Hermansen K; Kolotkin RL; Hammer M; Zdravkovic M; Matthews D
    Prim Care Diabetes; 2010 Jul; 4(2):113-7. PubMed ID: 20444662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Liraglutide treatment in a patient with HIV, type 2 diabetes and sleep apnoea-hypopnoea syndrome.
    García de Lucas MD; Olalla Sierra J; Piña Fernández J
    Diabetes Metab; 2015 Feb; 41(1):102-3. PubMed ID: 25455831
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical pearls for initiating and utilizing liraglutide in patients with type 2 diabetes.
    Gross B
    J Pharm Pract; 2013 Apr; 26(2):144-50. PubMed ID: 23204146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy.
    Parks M; Rosebraugh C
    N Engl J Med; 2010 Mar; 362(9):774-7. PubMed ID: 20164475
    [No Abstract]   [Full Text] [Related]  

  • 26. Liraglutide: from clinical trials to clinical practice.
    Gough SC
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():33-40. PubMed ID: 22405267
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An overview of the pharmacokinetics, efficacy and safety of liraglutide.
    Bode B
    Diabetes Res Clin Pract; 2012 Jul; 97(1):27-42. PubMed ID: 22245694
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liraglutide-related cholelithiasis.
    Korkmaz H; Araz M; Alkan S; Akarsu E
    Aging Clin Exp Res; 2015 Oct; 27(5):751-3. PubMed ID: 25725635
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial.
    Hermansen K; Bækdal TA; Düring M; Pietraszek A; Mortensen LS; Jørgensen H; Flint A
    Diabetes Obes Metab; 2013 Nov; 15(11):1040-8. PubMed ID: 23683069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Q: Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis?
    Olansky L
    Cleve Clin J Med; 2010 Aug; 77(8):503-5. PubMed ID: 20682512
    [No Abstract]   [Full Text] [Related]  

  • 31. Effect of three different injection sites on the pharmacokinetics of the once-daily human GLP-1 analogue liraglutide.
    Kapitza C; Zdravkovic M; Zijlstra E; Segel S; Heise T; Flint A
    J Clin Pharmacol; 2011 Jun; 51(6):951-5. PubMed ID: 20671294
    [No Abstract]   [Full Text] [Related]  

  • 32. The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis.
    Vrang N; Jelsing J; Simonsen L; Jensen AE; Thorup I; Søeborg H; Knudsen LB
    Am J Physiol Endocrinol Metab; 2012 Jul; 303(2):E253-64. PubMed ID: 22589391
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of liraglutide on male fertility: a case report.
    Fontoura P; Cardoso MC; Erthal-Martins MC; Werneck C; Sartorio C; Ramos CF
    Reprod Biomed Online; 2014 Nov; 29(5):644-6. PubMed ID: 25246122
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.
    Horowitz M; Flint A; Jones KL; Hindsberger C; Rasmussen MF; Kapitza C; Doran S; Jax T; Zdravkovic M; Chapman IM
    Diabetes Res Clin Pract; 2012 Aug; 97(2):258-66. PubMed ID: 22446097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes.
    Nauck MA; Hompesch M; Filipczak R; Le TD; Zdravkovic M; Gumprecht J;
    Exp Clin Endocrinol Diabetes; 2006 Sep; 114(8):417-23. PubMed ID: 17039422
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liraglutide in oral antidiabetic drug combination therapy.
    Garber AJ
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():13-9. PubMed ID: 22405265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany.
    Miller LA; Burudpakdee C; Zagar A; Bhosle M; Reaney M; Schabert VF; Bruhn D
    J Med Econ; 2012; 15(4):746-57. PubMed ID: 22443463
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vesiculopustular dermatosis: an uncommon side-effect of liraglutide?
    Besemer F; Verschoor AJ; Diamant M; Hoogma RP
    J Diabetes Complications; 2012; 26(5):458-9. PubMed ID: 22727533
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Scientific report: a case of acute pancreatitis due to liraglutide.
    Quesada-Vázquez N
    Rev Esp Enferm Dig; 2019 Apr; 111(4):329-330. PubMed ID: 30561221
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pancreatic safety in Japanese patients with type 2 diabetes treated with once weekly dulaglutide 0.75 mg up to 52 weeks in phase 3 clinical trials.
    Emoto M; Oura T; Matsui A; Kazama H; Iwamoto N
    Endocr J; 2017 Feb; 64(2):191-206. PubMed ID: 27853058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.